Publication | Closed Access

A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)

Metabolic SyndromeCardiovascular DiseaseOmega-3 Fatty AcidMedicineDiabetesHyperlipidemiaStatin-treated PatientsPharmacologyAtherosclerosisEsprit TrialDyslipidemiaCardiovascular Risk Profile